Trial Profile
An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 28 Feb 2024
Price :
$35
*
At a glance
- Drugs Bintrafusp alfa (Primary) ; Pembrolizumab
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms INTR@PID Lung 037
- Sponsors EMD Serono Research & Development Institute; Merck KGaA
- 21 Feb 2024 Planned End Date changed from 24 Mar 2024 to 30 Jun 2024.
- 24 Oct 2023 Planned End Date changed from 14 Nov 2023 to 24 Mar 2024.
- 17 Aug 2023 Primary endpoint (Overall Survival (OS)) has not been met, according to a results published in the Journal of Thoracic Oncology.